These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 12852716)

  • 1. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000.
    O'Brien JA; Patrick AR; Caro J
    Clin Ther; 2003 Mar; 25(3):1017-38. PubMed ID: 12852716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
    O'Brien JA; Patrick AR; Caro JJ
    BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct medical costs of complications resulting from type 2 diabetes in the U.S.
    O'Brien JA; Shomphe LA; Kavanagh PL; Raggio G; Caro JJ
    Diabetes Care; 1998 Jul; 21(7):1122-8. PubMed ID: 9653606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012).
    Ward A; Alvarez P; Vo L; Martin S
    J Med Econ; 2014 Mar; 17(3):176-83. PubMed ID: 24410011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes in Canada: direct medical costs of major macrovascular complications.
    O'Brien JA; Caro I; Getsios D; Caro JJ
    Value Health; 2001; 4(3):258-65. PubMed ID: 11705187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.
    Chen HY; Kuo S; Su PF; Wu JS; Ou HT
    Diabetes Care; 2020 Aug; 43(8):1732-1740. PubMed ID: 32444454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
    Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
    J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The health care costs of diabetic nephropathy in the United States and the United Kingdom.
    Gordois A; Scuffham P; Shearer A; Oglesby A
    J Diabetes Complications; 2004; 18(1):18-26. PubMed ID: 15019595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
    Martin S; Schramm W; Schneider B; Neeser K; Weber C; Lodwig V; Heinemann L; Scherbaum WA; Kolb H
    Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):495-501. PubMed ID: 17853332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lifetime costs of complications resulting from type 2 diabetes in the U.S.
    Caro JJ; Ward AJ; O'Brien JA
    Diabetes Care; 2002 Mar; 25(3):476-81. PubMed ID: 11874933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of the economic and health impact of complications of type 2 diabetes mellitus in the autonomous community of Madrid (Spain).
    Arrieta F; Rubio-Terrés C; Rubio-Rodríguez D; Magaña A; Piñera M; Iglesias P; Nogales P; Calañas A; Novella B; Botella-Carretero JI; Debán C; Zamarrón I; Mora G; Balsa JA; Vázquez C;
    Endocrinol Nutr; 2014 Apr; 61(4):193-201. PubMed ID: 24440211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
    Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
    Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of macrovascular complications in people with diabetes from a public healthcare perspective: a retrospective database study in Brazil.
    Julian GS; Campos D; Broe Honore J; Sauer Tobaruella F; Hyun Yoon J; Hallén N
    J Med Econ; 2020 Sep; 23(9):985-993. PubMed ID: 32372710
    [No Abstract]   [Full Text] [Related]  

  • 15. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.
    Zhuo X; Zhang P; Hoerger TJ
    Am J Prev Med; 2013 Sep; 45(3):253-61. PubMed ID: 23953350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual direct medical costs associated with diabetes-related complications in the event year and in subsequent years in Hong Kong.
    Jiao F; Wong CKH; Tang SCW; Fung CSC; Tan KCB; McGhee S; Gangwani R; Lam CLK
    Diabet Med; 2017 Sep; 34(9):1276-1283. PubMed ID: 28636749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus.
    Maetzel A; Ruof J; Covington M; Wolf A
    Pharmacoeconomics; 2003; 21(7):501-12. PubMed ID: 12696990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Costs of long-term complications in type 2 diabetes patients in Germany. Results of the CODE-2 Study].
    Liebl A; Spannheimer A; Reitberger U; Görtz A
    Med Klin (Munich); 2002 Dec; 97(12):713-9. PubMed ID: 12491064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the impact of complications on the costs of Type II diabetes.
    Williams R; Van Gaal L; Lucioni C;
    Diabetologia; 2002 Jul; 45(7):S13-7. PubMed ID: 12136406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.
    O'Brien JA; Caro JJ
    Pharmacoeconomics; 2002; 20(9):603-15. PubMed ID: 12141888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.